Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Nov 1;100(9):2386–2392. doi: 10.1172/JCI119779

Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.

I Shimon 1, X Yan 1, J E Taylor 1, M H Weiss 1, M D Culler 1, S Melmed 1
PMCID: PMC508437  PMID: 9410919

Abstract

Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation of growth hormone (GH), thyroid-stimulating hormone, and prolactin (PRL) secretion in human fetal pituitary cultures, where GH and thyroid-stimulating hormone are mediated by both SSTR2 and SSTR5, whereas SSTR2 preferentially mediates PRL secretion. We now tested SSTR subtype-selective analogues in primary human GH- and PRL-secreting pituitary adenoma cultures. Analogue affinities determined by membrane radioligand binding in cells stably expressing human SSTR forms were either SSTR2 or SSTR5-selective. Analogues preferential either for SSTR2, including octreotide, lanreotide, and novel compounds with improved affinity for SSTR2, or new SSTR5-selective compounds suppressed GH in tumor cell cultures (up to 44% of control; P < 0.0005). However, novel analogues from both groups were 30-40% more potent than octreotide and lanreotide in suppressing GH (P < 0.05). Heterologous analogue combinations containing both SSTR2- and SSTR5-selective compounds were more potent in decreasing GH than analogues used alone (P < 0.05), or than combinations of compounds specific for the same receptor subtype (P < 0.005). In contrast, SSTR2-selective analogues did not suppress PRL release from six cultured prolactinomas studied. However, new SSTR5-selective analogues suppressed in vitro PRL secretion (30-40%; P < 0.05) in four of six prolactinomas. These results suggest that both SSTR2 and SSTR5 are involved in GH regulation in somatotroph adenoma cells, whereas SSTR5 exclusively regulates PRL secretion from prolactinoma cells. Thus, somatostatin analogues with improved selective binding affinity for these receptor subtypes may be effective in the treatment of either GH- or PRL-secreting adenomas.

Full Text

The Full Text of this article is available as a PDF (198.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asa S. L., Kovacs K., Horvath E., Losinski N. E., Laszlo F. A., Domokos I., Halliday W. C. Human fetal adenohypophysis. Electron microscopic and ultrastructural immunocytochemical analysis. Neuroendocrinology. 1988 Oct;48(4):423–431. doi: 10.1159/000125044. [DOI] [PubMed] [Google Scholar]
  2. Berezin M., Shimon I., Hadani M. Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest. 1995 Jun;18(6):436–441. doi: 10.1007/BF03349742. [DOI] [PubMed] [Google Scholar]
  3. Bronstein M. D., Knoepfelmacher M., Liberman B., Marino R., Jr, Germek O. A., Schally A. V. Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm Metab Res. 1987 Jun;19(6):271–274. doi: 10.1055/s-2007-1011796. [DOI] [PubMed] [Google Scholar]
  4. Caron P., Morange-Ramos I., Cogne M., Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 1997 Jan;82(1):18–22. doi: 10.1210/jcem.82.1.3714. [DOI] [PubMed] [Google Scholar]
  5. Coy D. H., Taylor J. E. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism. 1996 Aug;45(8 Suppl 1):21–23. doi: 10.1016/s0026-0495(96)90073-6. [DOI] [PubMed] [Google Scholar]
  6. Ezzat S., Snyder P. J., Young W. F., Boyajy L. D., Newman C., Klibanski A., Molitch M. E., Boyd A. E., Sheeler L., Cook D. M. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992 Nov 1;117(9):711–718. doi: 10.7326/0003-4819-117-9-711. [DOI] [PubMed] [Google Scholar]
  7. Fahlbusch R., Honegger J., Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am. 1992 Sep;21(3):669–692. [PubMed] [Google Scholar]
  8. Fløgstad A. K., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns C., Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997 Jan;82(1):23–28. doi: 10.1210/jcem.82.1.3572. [DOI] [PubMed] [Google Scholar]
  9. Greenman Y., Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 1994 Sep;79(3):724–729. doi: 10.1210/jcem.79.3.7521350. [DOI] [PubMed] [Google Scholar]
  10. Greenman Y., Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994 Feb;78(2):398–403. doi: 10.1210/jcem.78.2.8106629. [DOI] [PubMed] [Google Scholar]
  11. Herman V., Fagin J., Gonsky R., Kovacs K., Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab. 1990 Dec;71(6):1427–1433. doi: 10.1210/jcem-71-6-1427. [DOI] [PubMed] [Google Scholar]
  12. Ishibashi M., Yamaji T. Effects of hypophysiotropic factors on growth hormone and prolactin secretion from somatotroph adenomas in culture. J Clin Endocrinol Metab. 1985 May;60(5):985–993. doi: 10.1210/jcem-60-5-985. [DOI] [PubMed] [Google Scholar]
  13. Ishibashi M., Yamaji T. Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture. J Clin Endocrinol Metab. 1985 Mar;60(3):599–606. doi: 10.1210/jcem-60-3-599. [DOI] [PubMed] [Google Scholar]
  14. Kubota A., Yamada Y., Kagimoto S., Shimatsu A., Imamura M., Tsuda K., Imura H., Seino S., Seino Y. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest. 1994 Mar;93(3):1321–1325. doi: 10.1172/JCI117090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lamberts S. W., Zweens M., Klijn J. G., van Vroonhoven C. C., Stefanko S. Z., Del Pozo E. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 1986 Aug;25(2):201–212. doi: 10.1111/j.1365-2265.1986.tb01683.x. [DOI] [PubMed] [Google Scholar]
  16. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995 Dec;80(12):3395–3402. doi: 10.1210/jcem.80.12.8530571. [DOI] [PubMed] [Google Scholar]
  17. Miller G. M., Alexander J. M., Bikkal H. A., Katznelson L., Zervas N. T., Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab. 1995 Apr;80(4):1386–1392. doi: 10.1210/jcem.80.4.7714115. [DOI] [PubMed] [Google Scholar]
  18. Newman C. B., Melmed S., Snyder P. J., Young W. F., Boyajy L. D., Levy R., Stewart W. N., Klibanski A., Molitch M. E., Gagel R. F. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab. 1995 Sep;80(9):2768–2775. doi: 10.1210/jcem.80.9.7673422. [DOI] [PubMed] [Google Scholar]
  19. Panetta R., Patel Y. C. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci. 1995;56(5):333–342. doi: 10.1016/0024-3205(94)00956-2. [DOI] [PubMed] [Google Scholar]
  20. Pellegrini I., Rasolonjanahary R., Gunz G., Bertrand P., Delivet S., Jedynak C. P., Kordon C., Peillon F., Jaquet P., Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab. 1989 Sep;69(3):500–509. doi: 10.1210/jcem-69-3-500. [DOI] [PubMed] [Google Scholar]
  21. Reisine T., Bell G. I. Molecular biology of somatostatin receptors. Endocr Rev. 1995 Aug;16(4):427–442. doi: 10.1210/edrv-16-4-427. [DOI] [PubMed] [Google Scholar]
  22. Reubi J. C., Waser B., Schaer J. C., Markwalder R. Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995 Sep;80(9):2806–2814. doi: 10.1210/jcem.80.9.7673428. [DOI] [PubMed] [Google Scholar]
  23. Shimon I., Taylor J. E., Dong J. Z., Bitonte R. A., Kim S., Morgan B., Coy D. H., Culler M. D., Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest. 1997 Feb 15;99(4):789–798. doi: 10.1172/JCI119225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vikić-Topić S., Raisch K. P., Kvols L. K., Vuk-Pavlović S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab. 1995 Oct;80(10):2974–2979. doi: 10.1210/jcem.80.10.7559883. [DOI] [PubMed] [Google Scholar]
  25. Webster J., Piscitelli G., Polli A., Ferrari C. I., Ismail I., Scanlon M. F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med. 1994 Oct 6;331(14):904–909. doi: 10.1056/NEJM199410063311403. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES